NFE2L2 and hepatocellular carcinoma: Withaferin A enhances sorafenib sensitivity in sorafenib-resistant hepatocellular carcinoma cells by regulating the Keap1/Nrf2-associated epithelial-to-mesenchymal transition (EMT) and ferroptosis[44].